Secondary Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer

Aliyah B. Conley; Keith F. Fournier; Anil K. Sood; Michael Frumovitz

doi:10.1097/AOG.0000000000005154

Secondary Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer

Aliyah B. Conley, Keith F. Fournier, Anil K. Sood, Michael Frumovitz

Gynecological Oncology & Reproductive Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND:Advanced or recurrent primary mucinous ovarian cancer is typically incurable and associated with short progression-free and overall survival when treated with standard chemotherapy. Novel approaches are desperately needed for women with this disease.CASES:Two patients with advanced or recurrent primary mucinous ovarian cancer were treated with secondary cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). No additional chemotherapy was administered postoperatively. Both patients achieved a complete and durable response, with no evidence of recurrence at 21 and 27 months, respectively, after CRS with HIPEC.CONCLUSION:Secondary CRS with HIPEC represents a potential therapeutic option for women with recurrent primary mucinous ovarian cancer.

Original language	English (US)
Pages (from-to)	1019-1023
Number of pages	5
Journal	Obstetrics and gynecology
Volume	141
Issue number	5
DOIs	https://doi.org/10.1097/AOG.0000000000005154
State	Published - May 1 2023

ASJC Scopus subject areas

Obstetrics and Gynecology

Access to Document

10.1097/AOG.0000000000005154

Cite this

@article{99b5dc6d29ec45a08fe6f3cf092f42ec,

title = "Secondary Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer",

abstract = "BACKGROUND:Advanced or recurrent primary mucinous ovarian cancer is typically incurable and associated with short progression-free and overall survival when treated with standard chemotherapy. Novel approaches are desperately needed for women with this disease.CASES:Two patients with advanced or recurrent primary mucinous ovarian cancer were treated with secondary cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). No additional chemotherapy was administered postoperatively. Both patients achieved a complete and durable response, with no evidence of recurrence at 21 and 27 months, respectively, after CRS with HIPEC.CONCLUSION:Secondary CRS with HIPEC represents a potential therapeutic option for women with recurrent primary mucinous ovarian cancer.",

author = "Conley, {Aliyah B.} and Fournier, {Keith F.} and Sood, {Anil K.} and Michael Frumovitz",

note = "Publisher Copyright: {\textcopyright} 2023 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc.",

year = "2023",

month = may,

day = "1",

doi = "10.1097/AOG.0000000000005154",

language = "English (US)",

volume = "141",

pages = "1019--1023",

journal = "Obstetrics and gynecology",

issn = "0029-7844",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Secondary Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer

AU - Conley, Aliyah B.

AU - Fournier, Keith F.

AU - Sood, Anil K.

AU - Frumovitz, Michael

PY - 2023/5/1

Y1 - 2023/5/1

N2 - BACKGROUND:Advanced or recurrent primary mucinous ovarian cancer is typically incurable and associated with short progression-free and overall survival when treated with standard chemotherapy. Novel approaches are desperately needed for women with this disease.CASES:Two patients with advanced or recurrent primary mucinous ovarian cancer were treated with secondary cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). No additional chemotherapy was administered postoperatively. Both patients achieved a complete and durable response, with no evidence of recurrence at 21 and 27 months, respectively, after CRS with HIPEC.CONCLUSION:Secondary CRS with HIPEC represents a potential therapeutic option for women with recurrent primary mucinous ovarian cancer.

AB - BACKGROUND:Advanced or recurrent primary mucinous ovarian cancer is typically incurable and associated with short progression-free and overall survival when treated with standard chemotherapy. Novel approaches are desperately needed for women with this disease.CASES:Two patients with advanced or recurrent primary mucinous ovarian cancer were treated with secondary cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). No additional chemotherapy was administered postoperatively. Both patients achieved a complete and durable response, with no evidence of recurrence at 21 and 27 months, respectively, after CRS with HIPEC.CONCLUSION:Secondary CRS with HIPEC represents a potential therapeutic option for women with recurrent primary mucinous ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=85156194740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85156194740&partnerID=8YFLogxK

U2 - 10.1097/AOG.0000000000005154

DO - 10.1097/AOG.0000000000005154

M3 - Article

C2 - 37023452

AN - SCOPUS:85156194740

SN - 0029-7844

VL - 141

SP - 1019

EP - 1023

JO - Obstetrics and gynecology

JF - Obstetrics and gynecology

IS - 5

ER -

Secondary Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this